Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 13, 2005. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction notification rather than comprehensive financial performance.
Material Changes
A material change occurred within the US Retirement Savings Plan ("The Plan") due to a re-valuation of the cash element of the notional investment held in GSK Ordinary Share ADRs. This resulted in an increase in the notional allocation of Ordinary Share ADRs on December 8, 2005, at a price of $50.68 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The unusual item noted is the specific transaction notification for Mr. D Pulman, involving an allocation of 1,061 shares, reported in accordance with Disclosure Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the impact of the US Retirement Savings Plan re-valuation on executive compensation or share ownership structures.
- Confirm the transaction details for Mr. D Pulman (1,061 shares at $50.68) against internal compliance records.
- Note that this filing does not contain quarterly or annual financial results; refer to Form 20-F for comprehensive financial data.